199 related articles for article (PubMed ID: 28647161)
1. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
Radley A; Tait J; Dillon JF
Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
[TBL] [Abstract][Full Text] [Related]
4.
Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
[TBL] [Abstract][Full Text] [Related]
5. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
Gunn J; Higgs P
Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
[TBL] [Abstract][Full Text] [Related]
6. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
Midgard H; Bramness JG; Skurtveit S; Haukeland JW; Dalgard O
PLoS One; 2016; 11(11):e0166451. PubMed ID: 27846264
[TBL] [Abstract][Full Text] [Related]
8. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study.
Grebely J; Dalgard O; Cunningham EB; Hajarizadeh B; Foster GR; Bruggmann P; Conway B; Backmund M; Robaeys G; Swan T; Amin J; Marks PS; Quiene S; Applegate TL; Weltman M; Shaw D; Dunlop A; Hellard M; Bruneau J; Midgard H; Bourgeois S; Staehelin C; Dore GJ;
Int J Drug Policy; 2017 Sep; 47():177-186. PubMed ID: 28624134
[TBL] [Abstract][Full Text] [Related]
10. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: An economic evaluation alongside a pragmatic cluster randomised trial.
Myring G; Lim AG; Hollingworth W; McLeod H; Beer L; Vickerman P; Hickman M; Radley A; Dillon JF
J Infect; 2022 Dec; 85(6):676-682. PubMed ID: 36170895
[TBL] [Abstract][Full Text] [Related]
12. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
13. Reaching people receiving opioid agonist therapy at community pharmacies with hepatitis C virus: an international randomised controlled trial.
Byrne CJ; Radley A; Inglis SK; Beer L; Palmer N; Duc Pham M; Allardice K; Wang H; Robinson E; Hermansson M; Semizarov D; Healy B; Doyle JS; Dillon JF
Aliment Pharmacol Ther; 2022 Jun; 55(12):1512-1523. PubMed ID: 35538396
[TBL] [Abstract][Full Text] [Related]
14. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
[TBL] [Abstract][Full Text] [Related]
15. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
16. A quasi-experimental evaluation of dried blood spot testing through community pharmacies in the Tayside region of Scotland.
Radley A; Melville K; Tait J; Stephens B; Evans JMM; Dillon JF
Frontline Gastroenterol; 2017 Jul; 8(3):221-228. PubMed ID: 28839912
[TBL] [Abstract][Full Text] [Related]
17. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection.
Grebely J; Genoway K; Khara M; Duncan F; Viljoen M; Elliott D; Raffa JD; DeVlaming S; Conway B
Int J Drug Policy; 2007 Oct; 18(5):437-43. PubMed ID: 17854734
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy.
Sasadeusz JJ; Dore G; Kronborg I; Barton D; Yoshihara M; Weltman M
Addiction; 2011 May; 106(5):977-84. PubMed ID: 21205057
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Grebely J; Mauss S; Brown A; Bronowicki JP; Puoti M; Wyles D; Natha M; Zhu Y; Yang J; Kreter B; Brainard DM; Yun C; Carr V; Dore GJ
Clin Infect Dis; 2016 Dec; 63(11):1405-1411. PubMed ID: 27553375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
